Fluorofenidone

Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) [1][2][3].

Product Specifications

CAS Number

[848353-85-5]

Product Name Alternative

AKF-PD

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

ERK; NF-κB; TGF-beta/Smad

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fluorofenidone.html

Purity

99.78

Solubility

DMSO : 140 mg/mL (ultrasonic)

Smiles

O=C1C=CC(C)=CN1C2=CC=CC(F)=C2

Molecular Formula

C12H10FNO

Molecular Weight

203.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Wu Y, et al. Fluorofenidone alleviates cigarette smoke exposure-induced chronic lung injury by targeting ferroptosis. Sci Rep. 2024 Dec 30;14 (1) :32149.|[2]Wang H, et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868 (12) :166556. |[3]Wang S, et al. Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression. Transl Lung Cancer Res. 2024 Nov 30;13 (11) :3175-3188.